![]() |
市場調查報告書
商品編碼
1497782
癌症診斷中的人工智慧市場:按組成部分、部署、癌症類型和最終用戶 - 2024-2030 年全球預測AI in Cancer Diagnostics Market by Component (Hardware, Services, Software), Deployment (Cloud, On-Premise), Cancer Type, End-user - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
癌症診斷領域的人工智慧市場規模預計2023年為2.2038億美元,2024年達到2.6628億美元,預計2030年將達到8.625億美元,複合年成長率為21.52%。
癌症診斷中的人工智慧 (AI) 涉及使用先進的演算法和軟體來處理、分析和解釋醫學影像和資料,以進行癌症檢測、診斷和預測。這些由人工智慧主導的系統配備了機器學習和深度學習功能,使它們能夠從大量腫瘤資料中學習,並隨著時間的推移提高準確性和效率。全球人口中癌症盛行率的不斷上升以及對個人化醫療的需求不斷成長正在推動人工智慧在醫療保健領域的採用。此外,向非侵入性癌症診斷的快速轉變,及其在世界各地多個癌症篩檢計畫中的快速採用,正在推動人工智慧在癌症治療中的整合。然而,人工智慧整合癌症治療的高成本以及缺乏訓練有素的腫瘤學家正在影響人工智慧在癌症診斷市場的擴張。此外,政府投資支持的癌症診斷技術進步正在為市場成長創造有利可圖的機會。
主要市場統計 | |
---|---|
基準年[2023] | 22038萬美元 |
預測年份 [2024] | 26628萬美元 |
預測年份 [2030] | 8.625 億美元 |
複合年成長率(%) | 21.52% |
區域洞察
在包括美國和加拿大在內的美國地區,對早期檢測和個人化醫療的重視正在推動基於人工智慧的癌症診斷的需求。著名的研究機構和公司正在大力投資人工智慧研究,FDA 等監管機構也急於核准人工智慧診斷工具。公司和學術機構提交的人工智慧專利申請反映了用於診斷成像和基因組資料分析的機器學習演算法的創新。一旦解決了對隱私和準確性的擔憂,客戶通常會接受人工智慧驅動的醫療保健服務。許多歐盟國家正在透過政府舉措在醫療保健領域進行全面的人工智慧研發活動。在該地區,由於人口老化和癌症發病率上升,客戶對人工智慧在癌症診斷方面的需求很高。就顧客購買行為而言,歐洲傾向青睞符合嚴格 GDPR 法規的產品和服務。中東地區對智慧健康技術進行了大量投資,人工智慧癌症診斷工具的市場正在擴大。在亞太地區,隨著人口老化推動消費者需求,癌症診斷領域的人工智慧市場正在擴大。在亞太地區,客戶越來越精通技術,並對人工智慧醫療保健解決方案持開放態度,政府對人工智慧研究的支持正在為癌症診斷領域的人工智慧建立一個快速成長的市場。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在癌症診斷市場人工智慧中的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一個綜合工具,可以對癌症診斷市場人工智慧供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該領域競爭性質的寶貴見解,包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對人工智慧在癌症診斷市場中的當前地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[193 Pages Report] The AI in Cancer Diagnostics Market size was estimated at USD 220.38 million in 2023 and expected to reach USD 266.28 million in 2024, at a CAGR 21.52% to reach USD 862.50 million by 2030.
Artificial Intelligence (AI) in cancer diagnostics involves the use of advanced algorithms and software to process, analyze, and interpret medical images and data for the detection, diagnosis, and prediction of cancer. These AI-driven systems are equipped with machine learning and deep learning capabilities, which enable them to learn from vast amounts of oncological data, improving their accuracy and efficiency over time. The increasing prevalence of cancer among the global population and the rising need for personalized medicine boost the adoption of AI in the healthcare sector. Moreover, proliferating adoption in several cancer screening programs worldwide, along with the exponential shift towards non-invasive cancer diagnosis, drives AI integration in cancer therapy. However, the high cost of AI-integrated cancer therapies and the shortage of trained oncologists impact the expansion of AI in the cancer diagnostics market. Furthermore, technological improvements in cancer diagnostics supported by government investments create lucrative opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 220.38 million |
Estimated Year [2024] | USD 266.28 million |
Forecast Year [2030] | USD 862.50 million |
CAGR (%) | 21.52% |
Regional Insights
In the American region, including the United States & Canada, the demand for AI-based cancer diagnostics is driven by a strong emphasis on early detection and personalized medicine. Prominent institutions and companies are investing heavily in AI research, and regulatory agencies such as the FDA are expediting approvals of AI diagnostic tools. Patent filings in AI from companies and academic institutions reflect the innovation in machine learning algorithms for imaging and genomic data analysis. Customers are generally receptive to AI-driven healthcare services, provided privacy and accuracy concerns are addressed. A host of EU countries engage in comprehensive AI research and development activities in the healthcare sector through government initiatives. The region shows a strong customer need for AI in cancer diagnostics due to aging populations and increased cancer prevalence. In terms of customer purchasing behavior, Europeans tend to favor products and services that comply with stringent GDPR regulations. In the Middle East, with substantial investments in smart health technologies, there's a growing market for AI cancer diagnostic tools. APAC region has a growing market for AI in cancer diagnostics, with its aging population driving consumer needs. In the APAC region, customers are increasingly tech-savvy and open to AI healthcare solutions, while the government's support of AI research has established a burgeoning market for AI in cancer diagnostics.
Market Insights
The market dynamics represent an ever-changing landscape of the AI in Cancer Diagnostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the AI in Cancer Diagnostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the AI in Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer
Biotechnology firm Owkin has solidified a partnership with MSD, known as Merck & Co. in the United States, to pioneer AI-enhanced digital pathology diagnostics tailored for the European Union market. This groundbreaking collaboration aims to refine pre-screening methods for Microsatellite Instability-High (MSI-H), a genomic biomarker critical for prognosticating and guiding treatment in immunotherapy, specifically in cancers such as endometrial, gastric, small intestine, and biliary where MSI-H detection is currently not standard practice despite its significance. [Published On: 2023-12-19]
ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions
ConcertAI has established a pivotal multi-year strategic partnership with Memorial Sloan Kettering Cancer Center (MSK) to focus on driving the advancement and implementation of clinical AI algorithms and enhancing imaging workflow integration within clinical trials, as well as augmenting oncology clinical decisions. MSK heralds these advancements as a catalyst for precise diagnostics and better management of treatment, fueling a transformative shift within the radiology and AI community that promises a leap in cancer diagnosis and patient care. [Published On: 2023-11-14]
Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses
F. Hoffmann-La Roche Ltd. has announced collaborations with Ibex Medical Analytics and Amazon Web Services to enhance cancer diagnostics through the navify digital pathology platform, which integrates cutting-edge AI tools for improved accuracy and efficiency in diagnosing breast and prostate cancer. These innovative collaborations aim to streamline pathology workflows by providing secure access to AI-driven decision support, enabling pathologists to deliver precise and expedited patient care. [Published On: 2023-10-26]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the AI in Cancer Diagnostics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.
Market Segmentation & Coverage